Novo Nordisk A/S (FRA:NOVA)
Germany · Delayed Price · Currency is EUR 49.30
+1.30 (2.71%)
At close: Sep 1, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Victoza | 5.48B | Log In | Log In | Log In | Log In | Upgrade |
Victoza Growth | -62.53% | Log In | Log In | Log In | Log In | Upgrade |
Rare Blood Disorders | 12.14B | Log In | Log In | Log In | Log In | Upgrade |
Rare Blood Disorders Growth | 6.53% | Log In | Log In | Log In | Log In | Upgrade |
Rare Endocrine Disorders | 4.99B | Log In | Log In | Log In | Log In | Upgrade |
Rare Endocrine Disorders Growth | 61.19% | Log In | Log In | Log In | Log In | Upgrade |
Other Rare Disease | 1.51B | Log In | Log In | Log In | Log In | Upgrade |
Other Rare Disease Growth | -0.58% | Log In | Log In | Log In | Log In | Upgrade |
Other Diabetes Care | 2.12B | Log In | Log In | Log In | Log In | Upgrade |
Other Diabetes Care Growth | -4.97% | Log In | Log In | Log In | Log In | Upgrade |
Saxenda | 6.94B | Log In | Log In | Log In | Log In | Upgrade |
Saxenda Growth | -39.14% | Log In | Log In | Log In | Log In | Upgrade |
Long-Acting Insulin | 19.10B | Log In | Log In | Log In | Log In | Upgrade |
Long-Acting Insulin Growth | 9.98% | Log In | Log In | Log In | Log In | Upgrade |
Premix Insulin | 10.79B | Log In | Log In | Log In | Log In | Upgrade |
Premix Insulin Growth | 11.16% | Log In | Log In | Log In | Log In | Upgrade |
Fast-Acting Insulin | 18.52B | Log In | Log In | Log In | Log In | Upgrade |
Fast-Acting Insulin Growth | 21.20% | Log In | Log In | Log In | Log In | Upgrade |
Human Insulin | 6.97B | Log In | Log In | Log In | Log In | Upgrade |
Human Insulin Growth | -6.28% | Log In | Log In | Log In | Log In | Upgrade |
Ozempic | 120.34B | Log In | Log In | Log In | Log In | Upgrade |
Ozempic Growth | 15.83% | Log In | Log In | Log In | Log In | Upgrade |
Rybelsus | 23.30B | Log In | Log In | Log In | Log In | Upgrade |
Rybelsus Growth | 11.16% | Log In | Log In | Log In | Log In | Upgrade |
Wegovy | 58.21B | Log In | Log In | Log In | Log In | Upgrade |
Wegovy Growth | 83.78% | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | 11.54B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Diabetes & Obesity Care Operating Profit | 127.72B | Log In | Log In | Log In | Log In | Upgrade |
Diabetes & Obesity Care Operating Profit Growth | 26.80% | Log In | Log In | Log In | Log In | Upgrade |
Rare Disease Operating Profit | 620.00M | Log In | Log In | Log In | Log In | Upgrade |
Rare Disease Operating Profit Growth | 317.46% | Log In | Log In | Log In | Log In | Upgrade |
Other | 11.54B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 11.54B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
US Revenue | 167.40B | Log In | Log In | Log In | Log In | Upgrade |
US Revenue Growth | 21.13% | Log In | Log In | Log In | Log In | Upgrade |
EUCAN | 57.55B | Log In | Log In | Log In | Log In | Upgrade |
EUCAN Growth | 19.62% | Log In | Log In | Log In | Log In | Upgrade |
Emerging Markets | 29.52B | Log In | Log In | Log In | Log In | Upgrade |
Emerging Markets Growth | 21.97% | Log In | Log In | Log In | Log In | Upgrade |
APAC | 17.44B | Log In | Log In | Log In | Log In | Upgrade |
APAC Growth | 33.96% | Log In | Log In | Log In | Log In | Upgrade |
China | 18.50B | Log In | Log In | Log In | Log In | Upgrade |
China Growth | 9.95% | Log In | Log In | Log In | Log In | Upgrade |
China Revenue (Pre-FY2024 Reporting) | 18.50B | Log In | Log In | Log In | Log In | Upgrade |
China Revenue (Pre-FY2024 Reporting) Growth | 9.95% | Log In | Log In | Log In | Log In | Upgrade |
US Revenue (Pre-FY2024 Reporting) | 167.40B | Log In | Log In | Log In | Log In | Upgrade |
US Revenue (Pre-FY2024 Reporting) Growth | 21.13% | Log In | Log In | Log In | Log In | Upgrade |
Other North American Operations (NAO) | 10.77B | Log In | Log In | Log In | Log In | Upgrade |
Other North American Operations (NAO) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
EMEA | 60.40B | Log In | Log In | Log In | Log In | Upgrade |
EMEA Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Rest of World | 33.33B | Log In | Log In | Log In | Log In | Upgrade |
Rest of World Growth | - | Log In | Log In | Log In | Log In | Upgrade |